Current best practice in pulmonary rehabilitation for chronic obstructive pulmonary disease.

Abstract:

:Chronic obstructive pulmonary disease (COPD) is a chronic condition that negatively affects several patient-centered outcomes. Among these, exercise capacity, dyspnea, and quality of life are the most relevant. In this article, factors contributing to exercise limitation, increase in exercise-induced dyspnea, quality of life deterioration, and other pathophysiological aspects in patients with COPD are analyzed in detail. Pulmonary rehabilitation (PR) is an evidence-based, multidisciplinary, and comprehensive intervention for patients with chronic respiratory diseases who are symptomatic and often have decreased daily life activities. PR has been clearly shown to induce favorable and long-lasting effects on all patient-centered outcomes. In addition, PR appears to have positive (even if not conclusively demonstrated) effects on other important outcomes in patients with COPD: number and severity of exacerbations, healthcare resource utilization, and survival. The organization of PR treatment, its components, outcome assessment, and future directions are discussed in light of the most robust scientific evidence.

journal_name

Ther Adv Respir Dis

authors

de Blasio F,Polverino M

doi

10.1177/1753465812444712

subject

Has Abstract

pub_date

2012-08-01 00:00:00

pages

221-37

issue

4

eissn

1753-4658

issn

1753-4666

pii

1753465812444712

journal_volume

6

pub_type

杂志文章,评审
  • Use of temperature-controlled laminar airflow in the management of atopic asthma: clinical evidence and experience.

    abstract::Avoidance of allergens in the treatment of asthma has hitherto not achieved significant benefit despite the strong evidence that allergy both increases severity and contributes to exacerbations of asthma. House dust mite, cat and dog allergens are the most common perennial allergic triggers and most avoidance strategi...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465817690505

    authors: Warner JO

    更新日期:2017-04-01 00:00:00

  • An update on the use of indacaterol in patients with COPD.

    abstract::Current guidelines for the management of chronic obstructive pulmonary disease (COPD) establish that bronchodilator medications are central to the symptomatic treatment of the disease. Regular treatment with long-acting bronchodilators is recommended as more effective and convenient than short-acting bronchodilators, ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465810387810

    authors: Brienza NS,Amor-Carro O,Ramos-Barbón D

    更新日期:2011-02-01 00:00:00

  • Therapeutic management of patients with rheumatoid arthritis and associated interstitial lung disease: case report and literature review.

    abstract::Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that can present different extrarticular manifestations involving heart, lungs and kidneys. In recent years there has been a growing awareness of the central role played by the lungs in the onset and progression of RA. In particular interstitial lung dise...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465816668780

    authors: Picchianti Diamanti A,Markovic M,Argento G,Giovagnoli S,Ricci A,Laganà B,D'Amelio R

    更新日期:2017-01-01 00:00:00

  • Applications and mechanisms of immunotherapy in allergic rhinitis and asthma.

    abstract::Clinical and immunologic tolerance are hallmarks of successful allergen immunotherapy (AIT). Clinical benefits such as reduced symptoms, pharmacotherapy intake and improvement of quality of life persist following cessation of treatment. Successful AIT is associated with suppression of allergic inflammatory cells such ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465816669662

    authors: Kappen JH,Durham SR,Veen HI,Shamji MH

    更新日期:2017-01-01 00:00:00

  • Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.

    abstract::Programmed cell death (PD)-1 immune checkpoint inhibitors have emerged as promising options for the treatment of multiple cancer types. Nivolumab is a fully human immunoglobulin G4 monoclonal antibody, which inhibits the PD-1 receptor and has been approved in the United States, Europe, and Asia for the treatment of ad...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753466618801167

    authors: Hida T

    更新日期:2018-01-01 00:00:00

  • Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis.

    abstract:BACKGROUND:Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is well known as a life-threatening condition during its clinical course. However, the clinical features and prognosis in AE of unclassifiable idiopathic interstitial pneumonia (AE-UCIIP) remain to be elucidated. The aim of this study was to clarif...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620935774

    authors: Enomoto N,Naoi H,Aono Y,Katsumata M,Horiike Y,Yasui H,Karayama M,Hozumi H,Suzuki Y,Furuhashi K,Fujisawa T,Inui N,Nakamura Y,Suda T

    更新日期:2020-01-01 00:00:00

  • Quantitative measurement properties and score interpretation of the Cough Severity Diary in patients with chronic cough.

    abstract:AIMS:The Cough Severity Diary (CSD) was developed in accordance with the FDA guidance for patient-reported outcome measures and is focused on capturing the patient's perception of cough in terms of frequency, intensity, and disruption due to their cough. The measure includes a series of seven items asking patients to r...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620915155

    authors: Martin Nguyen A,Bacci E,Dicpinigaitis P,Vernon M

    更新日期:2020-01-01 00:00:00

  • Factors determining the quality of life of patients with COPD in primary care.

    abstract:OBJECTIVES:To describe the health-related quality of life (HRQL) in a cohort of COPD patients recruited in primary care and identify the variables of the patients and the treatment associated with impaired HRQL. METHOD:Multicenter, observational study of patients with COPD recruited in Primary Care centers. Data regar...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,多中心研究

    doi:10.1177/1753465807086097

    authors: Miravitlles M,Molina J,Naberan K,Cots JM,Ros F,Llor C,EVOCA study.

    更新日期:2007-12-01 00:00:00

  • The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension.

    abstract::In recent years in the management of pulmonary arterial hypertension (PAH), endothelin receptor antagonists (ERAs) represent a well-established class of therapeutic agents with clear beneficial effects. Macitentan (Opsumit®), a dual ERA optimized for efficacy and safety, is the newest drug in the class. Macitentan pre...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753465814530182

    authors: Steriade A,Seferian A,Jaïs X,Savale L,Jutant EM,Parent F,Sitbon O,Humbert M,Simonneau G,Montani D

    更新日期:2014-06-01 00:00:00

  • Use of dry powder inhalers in acute exacerbations of asthma and COPD.

    abstract::To investigate whether dry powder inhalers (DPIs) function in a constrained situation, a literature analysis was performed to evaluate the use of DPIs compared with established therapies in the treatment of acute asthma and COPD, irrespective of rapid-acting beta(2)-agonist used. The external databases Medline, Embase...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465809103737

    authors: Selroos O,Borgström L,Ingelf J

    更新日期:2009-04-01 00:00:00

  • Experiences with treprostinil in the treatment of pulmonary arterial hypertension.

    abstract::Pulmonary arterial hypertension (PAH) is a chronic condition of elevated pulmonary arterial pressures with associated increases in pulmonary vascular resistance leading to right ventricular failure, which was almost uniformly fatal prior to the introduction of pulmonary hypertension specific therapy. Systemic prostacy...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465812455368

    authors: Stream AR,Bull TM

    更新日期:2012-10-01 00:00:00

  • Current approaches to pharmacotherapy for smoking cessation.

    abstract::It is well established that smoking is the primary preventable cause of disease and death in the United States and that it is responsible for a wide range of negative health consequences, including but not limited to respiratory disease. According to the US Public Health Service, all patients attempting to quit smokin...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465809353768

    authors: Hudmon KS,Corelli RL,Prokhorov AV

    更新日期:2010-02-01 00:00:00

  • Efficacy and safety profile of autologous blood versus talc pleurodesis for malignant pleural effusion: a randomized controlled trial.

    abstract:BACKGROUND:Autologous blood is a novel, high-efficacy sclerosant for treatment of malignant pleural effusion (MPE), similar to tetracycline. There has been no comparative data between autologous blood and a worldwide sclerosant like talc. We aimed to compare the effectiveness of autologous blood versus talc pleurodesis...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/1753466618816625

    authors: Keeratichananont W,Kaewdech A,Keeratichananont S

    更新日期:2018-01-01 00:00:00

  • Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma.

    abstract:OBJECTIVES:Pharmacologically mediated bronchodilation is important in the management of asthma, and is primarily achieved with β₂-agonists. Novel compounds should preferably have a longer duration of action and a better systemic side effect profile than established alternatives at comparable peak bronchodilation. This ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1177/1753465813497527

    authors: Bjermer L,Rosenborg J,Bengtsson T,Lötvall J

    更新日期:2013-10-01 00:00:00

  • Endoscopic lung volume reduction coil treatment in patients with very low FEV1: an observational study.

    abstract:BACKGROUND:Endoscopic lung volume reduction coil (LVRC) treatment is a therapeutic option for selected patients with advanced emphysema. The effects and the safety of endoscopic lung volume reduction in patients with very low forced expired volume in one second (FEV1) remain to be determined. This study was conducted t...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466618760133

    authors: Simon M,Harbaum L,Oqueka T,Kluge S,Klose H

    更新日期:2018-01-01 00:00:00

  • The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects.

    abstract::Long-acting bronchodilators are the cornerstone of pharmacologic treatment of chronic obstructive pulmonary disease (COPD). Spiolto® or Stiolto® is a fixed-dose combination (FDC) containing two long-acting bronchodilators, the long-acting muscarinic receptor antagonist tiotropium (TIO) and the long-acting β2-adrenocep...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753466619843426

    authors: Derom E,Brusselle GG,Joos GF

    更新日期:2019-01-01 00:00:00

  • Community versus hospital-acquired pneumonia in patients requiring extracorporeal membrane oxygenation.

    abstract:BACKGROUND:Bacterial pneumonia is a major cause of acute respiratory distress syndrome (ARDS) requiring extracorporeal membrane oxygenation (ECMO) support. However, it is unknown whether the type of pneumonia, community-acquired pneumonia (CAP) versus hospital-acquired pneumonia (HAP), should be considered when predict...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466618821038

    authors: Park C,Na SJ,Chung CR,Cho YH,Suh GY,Jeon K

    更新日期:2019-01-01 00:00:00

  • Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.

    abstract:BACKGROUND:Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease (ILD). Currently, two antifibrotic drugs are available for reducing forced vital capacity (FVC) decline in IPF. However, many pulmonologists wait before initiating treatment, especially when IPF patients have stable dise...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620953783

    authors: Aono Y,Nakamura Y,Kono M,Nakamura H,Yokomura K,Imokawa S,Toyoshima M,Yasui H,Hozumi H,Karayama M,Suzuki Y,Furuhashi K,Enomoto N,Fujisawa T,Inui N,Suda T

    更新日期:2020-01-01 00:00:00

  • Tolerability of inhaled N-chlorotaurine in humans: a double-blind randomized phase I clinical study.

    abstract:BACKGROUND:N-chlorotaurine (NCT), a long-lived oxidant produced by human leukocytes, can be synthesized chemically and used topically as a well-tolerated antiseptic to different body regions including sensitive ones. The aim of this study was to test the tolerability of inhaled 1% NCT in aqueous solution upon repeated ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1177/1753466618778955

    authors: Arnitz R,Stein M,Bauer P,Lanthaler B,Jamnig H,Scholl-Bürgi S,Stempfl-Al-Jazrawi K,Ulmer H,Baumgartner B,Embacher S,Geisler S,Gostner JM,Müllinger B,Kälz B,Nagl M

    更新日期:2018-01-01 00:00:00

  • The impact of comorbidities on mortality among men and women with COPD: report from the OLIN COPD study.

    abstract:BACKGROUND:Comorbidities probably contribute to the increased mortality observed among subjects with chronic obstructive pulmonary disease (COPD), but sex differences in the prognostic impact of comorbidities have rarely been evaluated in population-based studies. The aim of this study was to evaluate the impact of com...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466619860058

    authors: Sawalha S,Hedman L,Backman H,Stenfors N,Rönmark E,Lundbäck B,Lindberg A

    更新日期:2019-01-01 00:00:00

  • Beneficial role of vitamin D3 in the prevention of certain respiratory diseases.

    abstract::There is evidence of aberrations in the vitamin D-endocrine system in subjects with respiratory diseases. Vitamin D deficiency is highly prevalent in patients with respiratory diseases, and patients who receive vitamin D have significantly larger improvements in inspiratory muscle strength and maximal oxygen uptake. S...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465813503029

    authors: Luong KV,Nguyen LT

    更新日期:2013-12-01 00:00:00

  • Improving home oxygen therapy in patients with interstitial lung diseases: application of a noninvasive ventilation device.

    abstract:BACKGROUND:Proper adjustment of arterial oxygen saturation (SaO2) during daily activities in patients with interstitial lung disease (ILD) requiring long-term oxygen therapy is challenging. Given the multifactorial nature of the limited exercise tolerance in patients with ILDs, the isolated use of oxygen therapy may no...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620963027

    authors: Cuerpo S,Palomo M,Hernández-González F,Francesqui J,Albacar N,Hernández C,Blanco I,Embid C,Sellares J

    更新日期:2020-01-01 00:00:00

  • How will telemedicine change clinical practice in chronic obstructive pulmonary disease?

    abstract::Within telehealth there are a number of domains relevant to pulmonary care: telemonitoring, teleassistance, telerehabilitation, teleconsultation and second opinion calls. In the last decade, several studies focusing on the effects of various telemanagement programs for patients with chronic obstructive pulmonary disea...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465818754778

    authors: Vitacca M,Montini A,Comini L

    更新日期:2018-01-01 00:00:00

  • A comprehensive analysis of microRNAs as diagnostic biomarkers for asthma.

    abstract:BACKGROUND:It is unclear whether microRNAs could be a potential diagnostic biomarker for asthma or not. The objective of this study is to figure out the diagnostic value of microRNAs in asthma. METHODS:Literature retrieval, screening of publications, specific data extraction, and quality evaluation were conducted acco...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620981863

    authors: Xu L,Yi M,Tan Y,Yi Z,Zhang Y

    更新日期:2020-01-01 00:00:00

  • The influence of speleotherapy combined with pulmonary rehabilitation on functional fitness in older adults - preliminary report.

    abstract:OBJECTIVE:Our aim was to determine the influence of pulmonary rehabilitation conducted in therapeutic salt mine chambers on the functional fitness of older adults. METHODS:The study included 22 individuals of age >65 years with chronic respiratory conditions. The patients underwent the Fullerton test before and after ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620926952

    authors: Mętel S,Kostrzon M,Adamiak J,Gattner H,Kościelecka D,Sosulska A,Szczygieł E,Golec J

    更新日期:2020-01-01 00:00:00

  • Clinical and anti-inflammatory effects of ultra-short preseasonal vaccine to Parietaria in asthma.

    abstract:OBJECTIVE:The ultra-short course preseasonal allergy vaccine, containing the adjuvant monophosphoryl lipid A (MPL), is effective in treating allergic symptoms; however, the efficacy in controlling asthmatics symptoms has not been fully demonstrated. We aimed at evaluating whether the ultra-short preseasonal course of i...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753465813476564

    authors: Scichilone N,Scalici V,Arrigo R,Bellia V

    更新日期:2013-08-01 00:00:00

  • Nintedanib in non-small cell lung cancer: from preclinical to approval.

    abstract::Angiogenesis is a driving force of a tumor's development. Targeting this process is an attractive option, as this is a feature shared by most of the solid tumors. A lot of antiangiogenic drugs have been developed following this path, including bevacizumab, sorafenib, sunitinib, vandetanib, ramucirumab, motesanib and m...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465815579608

    authors: Caglevic C,Grassi M,Raez L,Listi A,Giallombardo M,Bustamante E,Gil-Bazo I,Rolfo C

    更新日期:2015-08-01 00:00:00

  • Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects.

    abstract::Maintenance pharmacological treatment for stable chronic obstructive pulmonary disease (COPD) is based on inhaled drugs, including long-acting muscarinic receptor antagonists (LAMA), long-acting β2-adrenoceptor agonists (LABA) and inhaled corticosteroids (ICS). Inhaled pharmacological treatment can improve patients' d...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753466618760779

    authors: Malerba M,Nardin M,Santini G,Mores N,Radaeli A,Montuschi P

    更新日期:2018-01-01 00:00:00

  • Baseline history of patients using selexipag for pulmonary arterial hypertension.

    abstract:INTRODUCTION:Since its introduction to the market in 2016, selexipag has been an alternative oral therapy among both treatment-naïve patients and those with mono or dual therapy failure; however, limited information is available regarding the presentation and management of patients with pulmonary arterial hypertension ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466619843774

    authors: Highland KB,Hull M,Pruett J,Elliott C,Tsang Y,Drake W

    更新日期:2019-01-01 00:00:00

  • The safety of asthma medications during pregnancy: an update for clinicians.

    abstract::Pregnancy may be complicated by new onset or preexisting asthma. This article reviews the recognition and management of asthma during pregnancy, as well as general principles of asthma medication use during pregnancy. ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753465814540029

    authors: Namazy JA,Schatz M

    更新日期:2014-08-01 00:00:00